Cargando…

Anti-RANKL treatment inhibits erosive joint destruction and lowers inflammation but has no effect on bone formation in the delayed-type hypersensitivity arthritis (DTHA) model

BACKGROUND: The aims of the present study were to determine the relationship between bone destruction and bone formation in the delayed-type hypersensitivity arthritis (DTHA) model and to evaluate the effect of receptor activator of nuclear factor κB ligand (RANKL) blockade on severity of arthritis,...

Descripción completa

Detalles Bibliográficos
Autores principales: Atkinson, Sara Marie, Bleil, Janine, Maier, René, Kühl, Anja A., Thorn, Mette, Serikawa, Kyle, Fox, Brian, Kruse, Kim, Haase, Claus, Skov, Søren, Nansen, Anneline, Syrbe, Uta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724155/
https://www.ncbi.nlm.nih.gov/pubmed/26801240
http://dx.doi.org/10.1186/s13075-016-0931-3
_version_ 1782411542919118848
author Atkinson, Sara Marie
Bleil, Janine
Maier, René
Kühl, Anja A.
Thorn, Mette
Serikawa, Kyle
Fox, Brian
Kruse, Kim
Haase, Claus
Skov, Søren
Nansen, Anneline
Syrbe, Uta
author_facet Atkinson, Sara Marie
Bleil, Janine
Maier, René
Kühl, Anja A.
Thorn, Mette
Serikawa, Kyle
Fox, Brian
Kruse, Kim
Haase, Claus
Skov, Søren
Nansen, Anneline
Syrbe, Uta
author_sort Atkinson, Sara Marie
collection PubMed
description BACKGROUND: The aims of the present study were to determine the relationship between bone destruction and bone formation in the delayed-type hypersensitivity arthritis (DTHA) model and to evaluate the effect of receptor activator of nuclear factor κB ligand (RANKL) blockade on severity of arthritis, bone destruction, and bone formation. METHODS: DTHA was induced in C57BL/6 mice. Inflammation, erosive joint damage, and new bone formation were semiquantitatively scored by histology. Osteoclast activity was assessed in vivo, and messenger RNA (mRNA) expression of mediators of bone destruction and bone formation were analyzed by mRNA deep sequencing. Serum concentrations of tartrate-resistant acid phosphatase 5b, carboxy-terminal telopeptide I (CTX-I), matrix metalloproteinase 3 (MMP3), and serum amyloid P component (SAP) were determined by enzyme-linked immunosorbent assay. Anti-RANKL monoclonal antibody treatment was initiated at the time of immunization. RESULTS: Bone destruction (MMP3 serum levels, cathepsin B activity, and RANKL mRNA) peaked at day 3 after arthritis induction, followed by a peak in cartilage destruction and bone erosion on day 5 after arthritis induction. Periarticular bone formation was observed from day 10. Induction of new bone formation indicated by enhanced Runx2, collagen X, osteocalcin, MMP2, MMP9, and MMP13 mRNA expression was observed only between days 8 and 11. Anti-RANKL treatment resulted in a modest reduction in paw and ankle swelling and a reduction of serum levels of SAP, MMP3, and CTX-I. Destruction of the subchondral bone was significantly reduced, while no effect on bone formation was seen. CONCLUSIONS: Anti-RANKL treatment prevents joint destruction but does not prevent new bone formation in the DTHA model. Thus, although occurring sequentially during the course of DTHA, bone destruction and bone formation are apparently not linked in this model.
format Online
Article
Text
id pubmed-4724155
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47241552016-01-24 Anti-RANKL treatment inhibits erosive joint destruction and lowers inflammation but has no effect on bone formation in the delayed-type hypersensitivity arthritis (DTHA) model Atkinson, Sara Marie Bleil, Janine Maier, René Kühl, Anja A. Thorn, Mette Serikawa, Kyle Fox, Brian Kruse, Kim Haase, Claus Skov, Søren Nansen, Anneline Syrbe, Uta Arthritis Res Ther Research Article BACKGROUND: The aims of the present study were to determine the relationship between bone destruction and bone formation in the delayed-type hypersensitivity arthritis (DTHA) model and to evaluate the effect of receptor activator of nuclear factor κB ligand (RANKL) blockade on severity of arthritis, bone destruction, and bone formation. METHODS: DTHA was induced in C57BL/6 mice. Inflammation, erosive joint damage, and new bone formation were semiquantitatively scored by histology. Osteoclast activity was assessed in vivo, and messenger RNA (mRNA) expression of mediators of bone destruction and bone formation were analyzed by mRNA deep sequencing. Serum concentrations of tartrate-resistant acid phosphatase 5b, carboxy-terminal telopeptide I (CTX-I), matrix metalloproteinase 3 (MMP3), and serum amyloid P component (SAP) were determined by enzyme-linked immunosorbent assay. Anti-RANKL monoclonal antibody treatment was initiated at the time of immunization. RESULTS: Bone destruction (MMP3 serum levels, cathepsin B activity, and RANKL mRNA) peaked at day 3 after arthritis induction, followed by a peak in cartilage destruction and bone erosion on day 5 after arthritis induction. Periarticular bone formation was observed from day 10. Induction of new bone formation indicated by enhanced Runx2, collagen X, osteocalcin, MMP2, MMP9, and MMP13 mRNA expression was observed only between days 8 and 11. Anti-RANKL treatment resulted in a modest reduction in paw and ankle swelling and a reduction of serum levels of SAP, MMP3, and CTX-I. Destruction of the subchondral bone was significantly reduced, while no effect on bone formation was seen. CONCLUSIONS: Anti-RANKL treatment prevents joint destruction but does not prevent new bone formation in the DTHA model. Thus, although occurring sequentially during the course of DTHA, bone destruction and bone formation are apparently not linked in this model. BioMed Central 2016-01-23 2016 /pmc/articles/PMC4724155/ /pubmed/26801240 http://dx.doi.org/10.1186/s13075-016-0931-3 Text en © Atkinson et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Atkinson, Sara Marie
Bleil, Janine
Maier, René
Kühl, Anja A.
Thorn, Mette
Serikawa, Kyle
Fox, Brian
Kruse, Kim
Haase, Claus
Skov, Søren
Nansen, Anneline
Syrbe, Uta
Anti-RANKL treatment inhibits erosive joint destruction and lowers inflammation but has no effect on bone formation in the delayed-type hypersensitivity arthritis (DTHA) model
title Anti-RANKL treatment inhibits erosive joint destruction and lowers inflammation but has no effect on bone formation in the delayed-type hypersensitivity arthritis (DTHA) model
title_full Anti-RANKL treatment inhibits erosive joint destruction and lowers inflammation but has no effect on bone formation in the delayed-type hypersensitivity arthritis (DTHA) model
title_fullStr Anti-RANKL treatment inhibits erosive joint destruction and lowers inflammation but has no effect on bone formation in the delayed-type hypersensitivity arthritis (DTHA) model
title_full_unstemmed Anti-RANKL treatment inhibits erosive joint destruction and lowers inflammation but has no effect on bone formation in the delayed-type hypersensitivity arthritis (DTHA) model
title_short Anti-RANKL treatment inhibits erosive joint destruction and lowers inflammation but has no effect on bone formation in the delayed-type hypersensitivity arthritis (DTHA) model
title_sort anti-rankl treatment inhibits erosive joint destruction and lowers inflammation but has no effect on bone formation in the delayed-type hypersensitivity arthritis (dtha) model
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724155/
https://www.ncbi.nlm.nih.gov/pubmed/26801240
http://dx.doi.org/10.1186/s13075-016-0931-3
work_keys_str_mv AT atkinsonsaramarie antirankltreatmentinhibitserosivejointdestructionandlowersinflammationbuthasnoeffectonboneformationinthedelayedtypehypersensitivityarthritisdthamodel
AT bleiljanine antirankltreatmentinhibitserosivejointdestructionandlowersinflammationbuthasnoeffectonboneformationinthedelayedtypehypersensitivityarthritisdthamodel
AT maierrene antirankltreatmentinhibitserosivejointdestructionandlowersinflammationbuthasnoeffectonboneformationinthedelayedtypehypersensitivityarthritisdthamodel
AT kuhlanjaa antirankltreatmentinhibitserosivejointdestructionandlowersinflammationbuthasnoeffectonboneformationinthedelayedtypehypersensitivityarthritisdthamodel
AT thornmette antirankltreatmentinhibitserosivejointdestructionandlowersinflammationbuthasnoeffectonboneformationinthedelayedtypehypersensitivityarthritisdthamodel
AT serikawakyle antirankltreatmentinhibitserosivejointdestructionandlowersinflammationbuthasnoeffectonboneformationinthedelayedtypehypersensitivityarthritisdthamodel
AT foxbrian antirankltreatmentinhibitserosivejointdestructionandlowersinflammationbuthasnoeffectonboneformationinthedelayedtypehypersensitivityarthritisdthamodel
AT krusekim antirankltreatmentinhibitserosivejointdestructionandlowersinflammationbuthasnoeffectonboneformationinthedelayedtypehypersensitivityarthritisdthamodel
AT haaseclaus antirankltreatmentinhibitserosivejointdestructionandlowersinflammationbuthasnoeffectonboneformationinthedelayedtypehypersensitivityarthritisdthamodel
AT skovsøren antirankltreatmentinhibitserosivejointdestructionandlowersinflammationbuthasnoeffectonboneformationinthedelayedtypehypersensitivityarthritisdthamodel
AT nansenanneline antirankltreatmentinhibitserosivejointdestructionandlowersinflammationbuthasnoeffectonboneformationinthedelayedtypehypersensitivityarthritisdthamodel
AT syrbeuta antirankltreatmentinhibitserosivejointdestructionandlowersinflammationbuthasnoeffectonboneformationinthedelayedtypehypersensitivityarthritisdthamodel